The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml TrialChristoph Röllig, Gerhard Ehninger, Carsten Müller‐Tidow et al.|Blood|2017Cited by 21
Clinical Characteristics and Outcome in IDH1/2 Mutant AML Patients - Analysis of 3898 Newly Diagnosed Patients with Acute Myeloid LeukemiaJan Moritz Middeke, Friedrich Stoelzel, Christoph Röllig et al.|Blood|2018Cited by 3